Neuronal TGase (TG6) ELISA

ZediXplore TG6-ELISA IgA and IgG (E003 / E004) are not available any more.
The ZediXclusive TG6-ab ELISA kits E103 and E104 are the revised versions of the ZediXplore TG6-ab ELISA kits E003 and E004

Improvements:
  • No need for background subtraction. Therefore, now you can measure up to 40 sera in duplicates with one kit.
  • The calibrators are adapted, so that the more relevant lower titers are covered. Titers (U/mL) obtained by the new E103/E104 kits can be translated to titers of old kit versions E003/E004 and vice versa!
  • Cutoffs are redefined based on a sera collective of 38 blood donors, equally distributed by sex and age, and a collective of 86 patients with various neurological disorders.


Art. No.
Name
Quantity
Price
E103 ZediXclusive TG6-ab ELISA (IgA)
Neuronal transglutaminase (TG6) ELISA IgA
1 Kit/96 wells
520 €
E104 ZediXclusive TG6-ab ELISA (IgG)
Neuronal transglutaminase (TG6) ELISA IgG
1 Kit/96 wells
520 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France